Healthcare / Diagnostics & ResearchHKSE
$7.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $56.4M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
44.1x
↑EV/EBITDA
24.1x
↑ROE
4.4%
↑Gross Margin
47.5%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.3%
FCF CAGR
—
FCF margin
-6.7%
FCF / Net income
-0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $247.2M · net income $27.0M · FCF $-16.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $247.2M | $247.2M | $164.2M | $151.3M | $145.7M |
| Net Income | $27.0M | $27.0M | $45.0M | $30.0M | $-17.6M |
| EBITDA | $49.7M | $49.7M | $70.0M | $52.4M | $-5.4M |
| EPS | — | — | 0.22 | 0.14 | -0.09 |
| Gross Margin | 47.5% | 47.5% | 72.7% | 58.4% | 56.1% |
| Operating Margin | 15.8% | 15.8% | 25.2% | 12.2% | 3.3% |
| Net Margin | 10.9% | 10.9% | 27.4% | 19.9% | -12.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.06 | 0.08 | 0.02 |
| Current Ratio | 3.64 | 3.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.7M | $-16.7M | $56.4M | $127.6M | $-12.1M |
| Returns | |||||
| ROE | 4.4% | 4.4% | 7.3% | 4.7% | -2.9% |
| Valuation | |||||
| P/E | 44.13 | 44.13 | 46.82 | 73.14 | — |
| EV/EBITDA | 24.10 | 24.10 | 24.00 | 32.41 | — |
| P/B | 2.59 | 2.59 | 3.48 | 3.36 | 4.14 |
| Growth & Yield | |||||
| Revenue Growth | 50.5% | 50.5% | 8.5% | 3.8% | — |
| EPS Growth | — | — | 57.1% | 255.6% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.22 → n/d
Residual
-1.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.